Murali Sharan, Sakthivel Manikandanesan, Pattabi Kamaraj, Venkatasamy Vettrichelvan, Thangaraj Jeromie Wesley Vivian, Shete Anita, Varghese Alby John, Arjun Jaganathan, Kumar Chethrapilly Purushothaman Girish, Yadav Pragya D, Sahay Rima, Majumdar Triparna, Dudhmal Manisha, Sivalingam Azhagendran, Dhanapal Sudha Rani, Durai Samy Augustine, Radhakrishnan Vijayaprabha, Muni Krishnaiah Murali Mohan, Arunachalam Suresh, Gandhi Punita Muni Krishna, Govindasamy Elavarasu, Chinnappan Prabhakaran, Sekar Dhana Priya Vadhani, Marappan Prakash, Pounraj Ezhil, Ganeshkumar Parasuraman, Jagadeesan Murugesan, Narnaware Manish, Bedi Gagandeep Singh, Kaur Prabhdeep, Murhekar Manoj
Indian Council of Medical Research-National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India.
Indian Council of Medical Research-National Institute of Virology, Pune 411001, India.
Vaccines (Basel). 2022 Jun 17;10(6):970. doi: 10.3390/vaccines10060970.
We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine's effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6-73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.
我们评估了两剂ChAdOx1 nCoV-19（Covishield）疫苗对印度泰米尔纳德邦金奈年龄≥45岁个体预防任何新冠病毒感染的有效性。2021年5月至9月在金奈选定的地理区域开展了一项基于社区的队列研究。估计样本量为10232。我们招募了69435名个体，其中21793名年龄在45岁以上。18岁及以上和45岁及以上年龄组Covishield的两剂接种覆盖率分别为18%和31%。从45岁及以上年龄组303名新冠病毒阳性个体采集的90份样本中的74份进行的基因组分析显示存在德尔塔变异株及其亚谱系。在接种第二剂Covishield至少2周后，该疫苗对45岁及以上年龄组新冠病毒疾病的有效性为61.3%（95%置信区间：43.6 - 73.4）。我们证明了两剂ChAdOx1疫苗对金奈普通人群中德尔塔变异株的有效性。我们建议未来开展类似研究，考虑新出现的变异株和新型疫苗。可确保两剂疫苗接种覆盖率以预防新冠病毒感染。
